New insider activity at Alnylam Pharma ( (ALNY) ) has taken place on March 4, 2025.
Fitzgerald Kevin Joseph, the Chief Scientific Officer and Executive Vice President, Head of Research at Alnylam Pharma, has recently sold 496 shares of the company’s stock. This transaction amounted to a total value of $119,877.
More about Alnylam Pharma
YTD Price Performance: 5.62%
Average Trading Volume: 684,753
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $31.94B